Non-Hodgkin Lymphoma Clinical Trials

64 studies are recruiting for non-hodgkin lymphoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

   Background: B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas. The drugs are venetoclax, ibrutinib, prednisone, obinutuzumab, and le…

   Stage

   Phase 1

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03223610 on ClinicalTrials.gov

2. Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

   This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing).

   Stage

   Phase 1

   Ages

   18 to 100

   Site

   City of Hope, Duarte, California

   Locations

   7 in total

   Run by

   Marker Therapeutics, Inc.

   See if you can join NCT05798897 on ClinicalTrials.gov

3. AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

   This study is designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Research Site, Duarte, California

   Locations

   39 in total

   Run by

   AstraZeneca

   See if you can join NCT06137144 on ClinicalTrials.gov

4. A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

   Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Alabama At Birmingham Hospital, Birmingham, Alabama

   Locations

   115 in total

   Run by

   BeOne Medicines

   See if you can join NCT05006716 on ClinicalTrials.gov

5. Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

   This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy. The purpose of this study is to identify the recommended dose of allogeneic NK cells in combination with IL-2, Tafasitamab and Rituximab for …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland, Ohio

   Locations

   2 in total

   Run by

   Paolo Caimi, MD

   See if you can join NCT07225439 on ClinicalTrials.gov

6. Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

   This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell NHL and CLL/SLL.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   H. Lee Moffitt Cancer Center, Tampa, Florida

   Locations

   15 in total

   Run by

   Imugene Limited

   See if you can join NCT03666000 on ClinicalTrials.gov

7. Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma

   The goal of this observational cohort study is to learn how toxin and occupational exposures, germline genetic variation, and immune dysregulation relate to B-cell non-Hodgkin lymphoma among active-duty service members and other Military Health System beneficiaries. The main questions are whether s…

   Stage

   Not phased

   Ages

   4 and older

   Site

   Walter Reed National Military Medical Center, Bethesda, Maryland

   Locations

   3 in total

   Run by

   Henry M. Jackson Foundation for the Advancement of Military Medicine

   See if you can join NCT07652580 on ClinicalTrials.gov

8. Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

   Background: Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV in the United States. People with HIV are up to 17 times more likely to get NHL than people who do not have HIV. The disease may also be different in these two groups. More study is needed for treating peo…

   Stage

   Phase 1

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05389423 on ClinicalTrials.gov

9. Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

   This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell ly…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California-Irvine Medical Center, Irvine, California

   Locations

   35 in total

   Run by

   Lyell Immunopharma, Inc.

   See if you can join NCT05826535 on ClinicalTrials.gov

10. LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

    This is a phase I, interventional, single arm, open label, treatment study designed to evaluate the safety and efficacy of LV20.19 CAR -T cells with pirtobrutinib bridging and maintenance in adult patients with B cell malignancies that have failed prior therapies.

    Stage

    Phase 1

    Ages

    18 to 81

    Site

    Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin

    Run by

    Medical College of Wisconsin

    See if you can join NCT05990465 on ClinicalTrials.gov

11. Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

    This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.

    Stage

    Phase 1

    Ages

    13 to 90

    Site

    City of Hope, Duarte, California

    Locations

    11 in total

    Run by

    Vironexis Biotherapeutics Inc.

    See if you can join NCT06533579 on ClinicalTrials.gov

12. A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

    The purpose of this study is to collect voice recordings and nervous system (neurologic) assessments from people with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM) who are receiving standard treatment with CAR T-cell therapy. Researchers will study whether these voice recordings and assessmen…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    8 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07249528 on ClinicalTrials.gov

13. Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)

    The SCORE-NHL study is a prospective, multi-center, study designed to collect data and biological samples from participants diagnosed with aggressive Stage I to IV non-Hodgkin Lymphoma (NHL). Study participants will undergo research blood collections of up to 60 mL as well as residual tissue collec…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Natera, Inc., Austin, Texas

    Run by

    Natera, Inc.

    See if you can join NCT07750886 on ClinicalTrials.gov

14. Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

    This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Banner MD Anderson Cancer Center, Gilbert, Arizona

    Locations

    11 in total

    Run by

    Miltenyi Biomedicine GmbH

    See if you can join NCT06116110 on ClinicalTrials.gov

15. A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

    This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Banner MD Anderson Cancer Center, Gilbert, Arizona

    Locations

    36 in total

    Run by

    Lyell Immunopharma, Inc.

    See if you can join NCT07188558 on ClinicalTrials.gov

16. A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

    The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in B-cell CLL, MM, and NHL participants with hypogammaglobulinemia (HGG) in…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    GC2202 Study Site 115, Huntington Park, California

    Locations

    62 in total

    Run by

    Grifols Therapeutics LLC

    See if you can join NCT05645107 on ClinicalTrials.gov

17. A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

    This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cel…

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    City of Hope Medical Center, Duarte, California

    Locations

    3 in total

    Run by

    City of Hope Medical Center

    See if you can join NCT07020533 on ClinicalTrials.gov

18. Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

    This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic diseases. Giving chemotherapy, such as cyclophosphamide, fludarabine and thiotepa, and TBI before …

    Stage

    Phase 2

    Ages

    0 to 65

    Site

    Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

    Run by

    Fred Hutchinson Cancer Center

    See if you can join NCT06013423 on ClinicalTrials.gov

19. Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

    This study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to collectively as lymphoma) whose disease has returned or not responded to treatment. Previous research combined antibodies and T cells to t…

    Stage

    Phase 1

    Ages

    12 to 75

    Site

    Houston Methodist Hospital, Houston, Texas

    Locations

    2 in total

    Run by

    Baylor College of Medicine

    See if you can join NCT06176690 on ClinicalTrials.gov

20. Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

    This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently completing prior treatment regimens) or patients who have received whole bra…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California

    Run by

    University of California, Irvine

    See if you can join NCT06580002 on ClinicalTrials.gov

21. Pre-malignant States to Hematologic Malignancies in Firefighters

    The purpose of the study is to evaluate if firefighter exposure to hazardous compounds will increase the incidence of premalignant hematological states which subsequently increases the risk of the development of hematologic malignancies, and potentially other pathophysiological consequences.

    Stage

    Not phased

    Ages

    40 to 49

    Site

    Levine Cancer Institute, Charlotte, North Carolina

    Run by

    Wake Forest University Health Sciences

    See if you can join NCT06870760 on ClinicalTrials.gov

22. Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

    This open-label, single arm phase 1 trial aims to determine the safety and tolerability of anti-CD19 and anti-CD22 chimeric antigen receptor-expressing (CAR) T cells (CD19x22 CAR T) in adolescents and adults with relapsed/refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL). This trial will determi…

    Stage

    Phase 1

    Ages

    16 and older

    Site

    University of Colorado Hospital, Aurora, Colorado

    Run by

    University of Colorado, Denver

    See if you can join NCT05098613 on ClinicalTrials.gov

23. A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

    This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

    Stage

    Not phased

    Ages

    Any age

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    142 in total

    Run by

    Center for International Blood and Marrow Transplant Research

    See if you can join NCT01351545 on ClinicalTrials.gov

24. Halt Aging in Survivors of Blood Cancers

    Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions. Whereas physical exercise can improve overall health, older cancer survivors do not meet the recommended physical activity, highlighting th…

    Stage

    Not phased

    Ages

    50 and older

    Site

    University of Nebraska Medical Center, Omaha, Nebraska

    Run by

    University of Nebraska

    See if you can join NCT07292272 on ClinicalTrials.gov

25. Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

    The goal of this clinical trial is to is to determine the safety, feasibility and efficacy of siltuximab prophylaxis of cytokine release syndrome and neurotoxicity occurring after epcoritamab subcutaneous administration for participants with large b-cell lymphoma (DLBCL) or follicular lymphoma (FL)…

    Stage

    Phase 1

    Ages

    18 to 65

    Site

    Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio

    Run by

    Taylor Brooks

    See if you can join NCT06447376 on ClinicalTrials.gov